167 related articles for article (PubMed ID: 28449585)
1. Elevated Plasma Aβ42 in Cognitively Impaired Individuals Taking ACE Inhibitor Antihypertensives.
Regenold WT; Blumenthal JB; Loreck DJ; Mordecai KL; Scarinzi G; Doddi SR; Adler L
Am J Alzheimers Dis Other Demen; 2017 Sep; 32(6):347-352. PubMed ID: 28449585
[TBL] [Abstract][Full Text] [Related]
2. The relationship of plasma Aβ levels to dementia in aging individuals with mild cognitive impairment.
Fei M; Jianghua W; Rujuan M; Wei Z; Qian W
J Neurol Sci; 2011 Jun; 305(1-2):92-6. PubMed ID: 21440911
[TBL] [Abstract][Full Text] [Related]
3. A clinical dose of angiotensin-converting enzyme (ACE) inhibitor and heterozygous ACE deletion exacerbate Alzheimer's disease pathology in mice.
Liu S; Ando F; Fujita Y; Liu J; Maeda T; Shen X; Kikuchi K; Matsumoto A; Yokomori M; Tanabe-Fujimura C; Shimokata H; Michikawa M; Komano H; Zou K
J Biol Chem; 2019 Jun; 294(25):9760-9770. PubMed ID: 31072831
[TBL] [Abstract][Full Text] [Related]
4. Plasma Aβ42 as a Biomarker of Prodromal Alzheimer's Disease Progression in Patients with Amnestic Mild Cognitive Impairment: Evidence from the PharmaCog/E-ADNI Study.
Albani D; Marizzoni M; Ferrari C; Fusco F; Boeri L; Raimondi I; Jovicich J; Babiloni C; Soricelli A; Lizio R; Galluzzi S; Cavaliere L; Didic M; Schönknecht P; Molinuevo JL; Nobili F; Parnetti L; Payoux P; Bocchio L; Salvatore M; Rossini PM; Tsolaki M; Visser PJ; Richardson JC; Wiltfang J; Bordet R; Blin O; Forloni G; Frisoni GB;
J Alzheimers Dis; 2019; 69(1):37-48. PubMed ID: 30149449
[TBL] [Abstract][Full Text] [Related]
5. Chemically treated plasma Aβ is a potential blood-based biomarker for screening cerebral amyloid deposition.
Park JC; Han SH; Cho HJ; Byun MS; Yi D; Choe YM; Kang S; Jung ES; Won SJ; Kim EH; Kim YK; Lee DY; Mook-Jung I
Alzheimers Res Ther; 2017 Mar; 9(1):20. PubMed ID: 28330509
[TBL] [Abstract][Full Text] [Related]
6. Elevation of Plasma Amyloid-β Level is More Significant in Early Stage of Cognitive Impairment: A Population-Based Cross-Sectional Study.
Wang J; Qiao F; Shang S; Li P; Chen C; Dang L; Jiang Y; Huo K; Deng M; Wang J; Qu Q
J Alzheimers Dis; 2018; 64(1):61-69. PubMed ID: 29865072
[TBL] [Abstract][Full Text] [Related]
7. Plasma Aβ42 and Total Tau Predict Cognitive Decline in Amnestic Mild Cognitive Impairment.
Chen TB; Lee YJ; Lin SY; Chen JP; Hu CJ; Wang PN; Cheng IH
Sci Rep; 2019 Sep; 9(1):13984. PubMed ID: 31562355
[TBL] [Abstract][Full Text] [Related]
8. A two-step immunoassay for the simultaneous assessment of Aβ38, Aβ40 and Aβ42 in human blood plasma supports the Aβ42/Aβ40 ratio as a promising biomarker candidate of Alzheimer's disease.
Shahpasand-Kroner H; Klafki HW; Bauer C; Schuchhardt J; Hüttenrauch M; Stazi M; Bouter C; Wirths O; Vogelgsang J; Wiltfang J
Alzheimers Res Ther; 2018 Dec; 10(1):121. PubMed ID: 30526652
[TBL] [Abstract][Full Text] [Related]
9. Ultrasensitive Detection of Plasma Amyloid-β as a Biomarker for Cognitively Normal Elderly Individuals at Risk of Alzheimer's Disease.
Chatterjee P; Elmi M; Goozee K; Shah T; Sohrabi HR; Dias CB; Pedrini S; Shen K; Asih PR; Dave P; Taddei K; Vanderstichele H; Zetterberg H; Blennow K; Martins RN
J Alzheimers Dis; 2019; 71(3):775-783. PubMed ID: 31424403
[TBL] [Abstract][Full Text] [Related]
10. Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease.
Graff-Radford NR; Crook JE; Lucas J; Boeve BF; Knopman DS; Ivnik RJ; Smith GE; Younkin LH; Petersen RC; Younkin SG
Arch Neurol; 2007 Mar; 64(3):354-62. PubMed ID: 17353377
[TBL] [Abstract][Full Text] [Related]
11. Characterization of insulin degrading enzyme and other amyloid-β degrading proteases in human serum: a role in Alzheimer's disease?
Liu Z; Zhu H; Fang GG; Walsh K; Mwamburi M; Wolozin B; Abdul-Hay SO; Ikezu T; Leissring MA; Qiu WQ
J Alzheimers Dis; 2012; 29(2):329-40. PubMed ID: 22232014
[TBL] [Abstract][Full Text] [Related]
12. Combination of gut microbiota and plasma amyloid-β as a potential index for identifying preclinical Alzheimer's disease: a cross-sectional analysis from the SILCODE study.
Sheng C; Yang K; He B; Du W; Cai Y; Han Y
Alzheimers Res Ther; 2022 Feb; 14(1):35. PubMed ID: 35164860
[TBL] [Abstract][Full Text] [Related]
13. Conversion of Aβ43 to Aβ40 by the successive action of angiotensin-converting enzyme 2 and angiotensin-converting enzyme.
Liu S; Liu J; Miura Y; Tanabe C; Maeda T; Terayama Y; Turner AJ; Zou K; Komano H
J Neurosci Res; 2014 Sep; 92(9):1178-86. PubMed ID: 24823497
[TBL] [Abstract][Full Text] [Related]
14. Brain Amyloid-β Deposition and Blood Biomarkers in Patients with Clinically Diagnosed Alzheimer's Disease.
Li WW; Shen YY; Tian DY; Bu XL; Zeng F; Liu YH; Chen Y; Yao XQ; Li HY; Chen DW; Zhou FY; Yang H; Li QM; Bao WQ; Guan YH; Zhou HD; Jin RB; Wang YJ
J Alzheimers Dis; 2019; 69(1):169-178. PubMed ID: 30958377
[TBL] [Abstract][Full Text] [Related]
15. Clinical performance of an antibody-free assay for plasma Aβ42/Aβ40 to detect early alterations of Alzheimer's disease in individuals with subjective cognitive decline.
Pascual-Lucas M; Allué JA; Sarasa L; Fandos N; Castillo S; Terencio J; Sarasa M; Tartari JP; Sanabria Á; Tárraga L; Ruíz A; Marquié M; Seo SW; Jang H; Boada M;
Alzheimers Res Ther; 2023 Jan; 15(1):2. PubMed ID: 36604729
[TBL] [Abstract][Full Text] [Related]
16. Plasma Abeta42 and Abeta40 as markers of cognitive change in follow-up: a prospective, longitudinal, population-based cohort study.
Seppälä TT; Herukka SK; Hänninen T; Tervo S; Hallikainen M; Soininen H; Pirttilä T
J Neurol Neurosurg Psychiatry; 2010 Oct; 81(10):1123-7. PubMed ID: 20478847
[TBL] [Abstract][Full Text] [Related]
17. Blood amyloid beta levels in healthy, mild cognitive impairment and Alzheimer's disease individuals: replication of diastolic blood pressure correlations and analysis of critical covariates.
Ruiz A; Pesini P; Espinosa A; Pérez-Grijalba V; Valero S; Sotolongo-Grau O; Alegret M; Monleón I; Lafuente A; Buendía M; Ibarria M; Ruiz S; Hernández I; San José I; Tárraga L; Boada M; Sarasa M
PLoS One; 2013; 8(11):e81334. PubMed ID: 24312290
[TBL] [Abstract][Full Text] [Related]
18. Plasma and cerebrospinal fluid ABeta42 for the differential diagnosis of Alzheimer's disease dementia in participants diagnosed with any dementia subtype in a specialist care setting.
Kokkinou M; Beishon LC; Smailagic N; Noel-Storr AH; Hyde C; Ukoumunne O; Worrall RE; Hayen A; Desai M; Ashok AH; Paul EJ; Georgopoulou A; Casoli T; Quinn TJ; Ritchie CW
Cochrane Database Syst Rev; 2021 Feb; 2(2):CD010945. PubMed ID: 33566374
[TBL] [Abstract][Full Text] [Related]
19. Multiplex immunoassay measurement of amyloid-β
Vogelgsang J; Shahpasand-Kroner H; Vogelgsang R; Streit F; Vukovich R; Wiltfang J
Exp Brain Res; 2018 May; 236(5):1241-1250. PubMed ID: 29480353
[TBL] [Abstract][Full Text] [Related]
20. Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease.
Mehta PD; Pirttilä T; Mehta SP; Sersen EA; Aisen PS; Wisniewski HM
Arch Neurol; 2000 Jan; 57(1):100-5. PubMed ID: 10634455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
